Price target: $120 Time frame: 1-2 years
A year after my original call (http://https://rchenmit.github.io/2016/08/13/gilead-one-mans-sickness-is-another-mans-profit/
), I am still long GILD. The positive drivers clearly outweigh the overblown fears.
the recent Kite Pharma acquisition Gilead will continue to print money with non-alcoholic steatohepatitis (NASH) drugs Overblown Fears:
“the hepatitis C (HCV) revenues are decreasing!” “the HCV patents are expiring!” The overblown fears should be non-issues.